RenaissanceTechnologies News & Analysis
3 articles
Market Mood
Apple (AAPL) Sets Record iPhone Revenue at $56.99 Billion Q2 2026
Renaissance Technologies has initiated a new position in Apple Inc. (AAPL), acquiring over 3 million shares in Q1 2026. In Q2 2026, Apple reported iPhone revenue of $56.99 billion, reflecting a 22% year-over-year increase, driven by strong demand for the iPhone 17 lineup. Additionally, services revenue reached a high of $30.98 billion, marking a 16% growth. Despite concerns about market slowdowns, Apple achieved double-digit revenue growth in all geographic segments, with Greater China sales jumping 28% to $20.5 billion, highlighting robust international demand.
Read More
Palantir Technologies (PLTR) Reports 133% Revenue Growth in Q1 2026
Palantir Technologies Inc. (PLTR) reported a 133% year-over-year increase in US Commercial revenue, reaching $595 million in Q1 2026. The number of total commercial customers rose to 1,007, marking a 31% growth year-over-year. Additionally, US Government revenue grew by 84% to $687 million during the same period. Renaissance Technologies trimmed its stake in PLTR by over 20%, owning just under 7 million shares as of Q1 2026, down from more than 47 million shares by early 2024.
Read More
United Therapeutics (UTHR) Ranks 1st in Renaissance Technologies 2026 List
United Therapeutics Corporation (UTHR) is ranked 1st on Renaissance Technologies' list of top stocks for 2026. The fund disclosed its initial stake of 261,000 shares in UTHR in Q4 2010. As of Q1 2026, Renaissance owns nearly 1.8 million shares, a decrease of over 6% from Q4 2025. The company is preparing major NDA submissions to the FDA for Tyvaso, which aims to be the first inhaled anti-fibrotic treatment for Idiopathic Pulmonary Fibrosis, following positive data from its TETON studies.
Read More